Legend Biotech Corp Stock Buy Hold or Sell Recommendation
| LEGN Stock | USD 37.20 0.85 2.23% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Legend Biotech Corp is 'Cautious Hold'. The recommendation algorithm takes into account all of Legend Biotech's available fundamental, technical, and predictive indicators you will find on this site.
Check out Legend Biotech Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Legend and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Legend Biotech Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
Legend |
Execute Legend Biotech Buy or Sell Advice
The Legend recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Legend Biotech Corp. Macroaxis does not own or have any residual interests in Legend Biotech Corp or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Legend Biotech's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Modest | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Legend Biotech Trading Alerts and Improvement Suggestions
| Legend Biotech Corp had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 627.24 M. Net Loss for the year was (158.13 M) with loss before overhead, payroll, taxes, and interest of (20.88 M). | |
| Legend Biotech Corp currently holds about 791.26 M in cash with (144.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.11. | |
| Roughly 55.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: HC Wainwright Forecasts Strong Price Appreciation for Legend Biotech Stock |
Legend Biotech Returns Distribution Density
The distribution of Legend Biotech's historical returns is an attempt to chart the uncertainty of Legend Biotech's future price movements. The chart of the probability distribution of Legend Biotech daily returns describes the distribution of returns around its average expected value. We use Legend Biotech Corp price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Legend Biotech returns is essential to provide solid investment advice for Legend Biotech.
| Mean Return | -0.11 | Value At Risk | -5.8 | Potential Upside | 6.15 | Standard Deviation | 3.43 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Legend Biotech historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Legend Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Legend Biotech, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Legend Biotech Corp back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | Massachusetts Financial Services Company | 2024-12-31 | 2.3 M | Capital Research & Mgmt Co - Division 3 | 2024-12-31 | 2.2 M | Hhg Plc | 2024-12-31 | 2.2 M | Wellington Management Company Llp | 2024-12-31 | 2.1 M | Deerfield Management Co | 2024-12-31 | 1.6 M | Artisan Partners Limited Partnership | 2024-12-31 | 1.5 M | Federated Hermes Inc | 2024-12-31 | 1.5 M | Alliancebernstein L.p. | 2024-12-31 | 1.5 M | Matthews International Cap Mgmt Llc | 2024-12-31 | 1.2 M | Fmr Inc | 2024-12-31 | 13.4 M | Ra Capital Management, Llc | 2024-12-31 | 7.5 M |
Legend Biotech Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | (643K) | 51K | (8.6M) | (12.7M) | (17.2M) | (16.3M) | |
| Investments | 25.6M | (195.0M) | (78.3M) | 92.8M | (850.5M) | (808.0M) | |
| Change In Cash | 372.3M | 233.2M | 97.1M | 491.7M | (991.0M) | (941.4M) | |
| Net Borrowings | 14.7M | (2.6M) | (1.4M) | (2.6M) | (2.3M) | (2.2M) | |
| Free Cash Flow | (272.8M) | (245.6M) | (222.3M) | (416.0M) | (158.1M) | (166.0M) | |
| Depreciation | 9.9M | 13.9M | 18.4M | 20.5M | 23.4M | 12.8M | |
| Other Non Cash Items | 84.6M | 187.7M | 6.6M | 128.2M | (98.2M) | (93.3M) | |
| Capital Expenditures | 49.8M | 47.1M | 22.3M | 22.7M | 14.1M | 13.4M | |
| Net Income | (307.6M) | (386.2M) | (445.7M) | (518.3M) | (158.1M) | (166.0M) | |
| End Period Cash Flow | 455.7M | 688.9M | 786.0M | 1.3B | 286.7M | 521.2M | |
| Change To Netincome | (7.8M) | 92.0M | 187.7M | 34.2M | 39.3M | 55.1M |
Legend Biotech Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Legend Biotech or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Legend Biotech's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Legend stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.13 | |
β | Beta against Dow Jones | -0.11 | |
σ | Overall volatility | 3.19 | |
Ir | Information ratio | -0.003 |
Legend Biotech Volatility Alert
Legend Biotech Corp exhibits very low volatility with skewness of 0.22 and kurtosis of 0.66. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Legend Biotech's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Legend Biotech's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Legend Biotech Fundamentals Vs Peers
Comparing Legend Biotech's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Legend Biotech's direct or indirect competition across all of the common fundamentals between Legend Biotech and the related equities. This way, we can detect undervalued stocks with similar characteristics as Legend Biotech or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Legend Biotech's fundamental indicators could also be used in its relative valuation, which is a method of valuing Legend Biotech by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Legend Biotech to competition |
| Fundamentals | Legend Biotech | Peer Average |
| Return On Equity | -0.15 | -0.31 |
| Return On Asset | -0.11 | -0.14 |
| Profit Margin | (0.28) % | (1.27) % |
| Operating Margin | (0.40) % | (5.51) % |
| Current Valuation | 6.06 B | 16.62 B |
| Shares Outstanding | 183.65 M | 571.82 M |
| Shares Owned By Insiders | 1.33 % | 10.09 % |
| Shares Owned By Institutions | 55.49 % | 39.21 % |
| Number Of Shares Shorted | 13.34 M | 4.71 M |
| Price To Book | 6.56 X | 9.51 X |
| Price To Sales | 10.89 X | 11.42 X |
| Revenue | 627.24 M | 9.43 B |
| Gross Profit | (20.88 M) | 27.38 B |
| EBITDA | (113.16 M) | 3.9 B |
| Net Income | (158.13 M) | 570.98 M |
| Cash And Equivalents | 791.26 M | 2.7 B |
| Cash Per Share | 5.11 X | 5.01 X |
| Total Debt | 350.6 M | 5.32 B |
| Debt To Equity | 0.29 % | 48.70 % |
| Current Ratio | 3.83 X | 2.16 X |
| Book Value Per Share | 5.67 X | 1.93 K |
| Cash Flow From Operations | (144.03 M) | 971.22 M |
| Short Ratio | 11.52 X | 4.00 X |
| Earnings Per Share | (0.96) X | 3.12 X |
| Target Price | 78.01 | |
| Number Of Employees | 2.6 K | 18.84 K |
| Beta | 0.2 | -0.15 |
| Market Capitalization | 6.83 B | 19.03 B |
| Total Asset | 1.67 B | 29.47 B |
| Retained Earnings | (1.66 B) | 9.33 B |
| Working Capital | 1.01 B | 1.48 B |
| Net Asset | 1.67 B |
Legend Biotech Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Legend . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Legend Biotech Buy or Sell Advice
When is the right time to buy or sell Legend Biotech Corp? Buying financial instruments such as Legend Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Legend Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Healthcare Thematic Idea Now
Healthcare
Companies that provide healthcare goods and services including hospitals, health maintenance organizations, HMOs, or medical aid manufacturers. The Healthcare theme has 20 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Healthcare Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Legend Biotech Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Legend Biotech. If investors know Legend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Legend Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.96) | Revenue Per Share | Quarterly Revenue Growth 1.347 | Return On Assets | Return On Equity |
The market value of Legend Biotech Corp is measured differently than its book value, which is the value of Legend that is recorded on the company's balance sheet. Investors also form their own opinion of Legend Biotech's value that differs from its market value or its book value, called intrinsic value, which is Legend Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Legend Biotech's market value can be influenced by many factors that don't directly affect Legend Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Legend Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Legend Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Legend Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.